bluuebunny/crossref_metadata_2025_split huggingface dataset:
MIR204 POTENTIALLY PROMOTES NON-ALCOHOLIC FATTY LIVER DISEASE BY INHIBITION OF CPT1A IN MOUSE HEPATOCYTES
Authors: Kim Seonhee , Kim Minsoo , Piao Shuyu , Giang Huong Vu , Choi Su-Jeong , Kim Cuk-Seong 
Published: June 2023

Objective:
Non-alcoholic fatty liver disease (NAFLD) is associated with hepatic metabolism dysfunction. However, the mechanistic role of miR204 in the development of NAFLD is unknown. We investigated the functional significance of miR204 in the evolution of NAFLD.

Design and method:
NAFLD was induced in isocitrate dehydrogenase (IDH2) knockout (KO) mice by feeding them with a high-fat diet (HFD). Blood parameters and hepatic fat accumulation were evaluated in IDH2 KO mice and wild-type (WT) mice. A miR204 inhibitor was subcutaneously injected into mice using an osmotic pump. The expression of miR204 was analyzed by quantitative PCR (qPCR).

Results:
IDH2 KO mice fed a normal diet (ND) or HFD showed significantly increased body weight, epididymal fat-pad weight, cholesterol, triglyceride, and macrophage marker (CD68), and inflammatory cytokine [tumor necrosis factor-a (TNF-a), interleukin (IL)-6 and IL-1b] expression compared to WT mice fed a ND or HFD. Moreover, the expression of miR204 was significantly increased in mice with IDH2 deficiency. miR204 regulates carnitine palmitoyltransferase 1a (cpt1a) synthesis, which inhibits fatty acid b-oxidation. Inhibition of miR204 prevents the disassembly of two fatty acid-related genes—peroxisomal acyl-coenzyme A oxidase 1 (ACOX-1) and peroxisome proliferator-activated receptor alpha (PPARa)—by activating CPT1a expression, which decreases inflammatory cytokines, epididymal fat pad weight, cholesterol, low-density lipoprotein (LDL), and triglycerides.

Conclusions:
miR204 promotes the pathogenesis of HFD-induced NAFLD by regulating hepatic metabolism and inflammation.
RELATIONSHIP OF HYPERURACEMIA WITH METABOLIC DISORDERS IN PATIENTS WITH ARTERIAL HYPERTENSION
Authors: Duysewnbaeva Aziza , Srojidinova Nigora , Saidakbarova Feruza 
Published: June 2023

Objective:
To study the prevalence of hyperuremia and to study its role in development of metabolic disorders in patients with arterial hypertension (AH).

Design and method:
The study analyzed 188 case histories of patients with AH grades 1-3 (ESC/ESH, 2018). 109 women and 79 men were studied. Mean age 62.8±10.2 years. Hyperuricemia was established with an increase in the level of uric acid > 7 mg / dl in men, > 5.7 mg / dl in women.

Results:
Results: For analysis, patients were divided into 2 groups: the first group consisted of patients with hyperuricemia (n = 103), the second - patients with normal levels of uric acid (n = 85). The average level of uric acid in the 1st group was 7.44±1.33 mg/dl, and in the 2nd group - 5.06±0.98 mg/dl, p<0.00001. The compared groups were similar in terms of age, office SBP and DBP. Age: 62.7±10.51 vs 62.8±10.01 years, p = 0.95; SBP - 136.82±22.09 mm Hg. vs 132.98±24.4 mmHg, p = 0.26; DBP - 85.17±10.27 mm Hg. vs 84.27±10.71 mmHg, p = 0.56. The groups also did not differ in BMI and WC: BMI-32.96±5.84 kg/m2 vs 31.24±5.00 kg/m2 p = 0.44; OT-105.44±13.75 cm vs 102.76±12.06 cm, p = 0.16. It should be noted that patients with hyperuricemia had a significantly high level of MAU: 63.24±104.06 vs 39.33±36.42 mg/l, p = 0.044. Patients with hyperuricemia had more pronounced dyslipidemia. Thus, total cholesterol was significantly high in group 1: 198.31±49.41 mg/dl vs 181.75±49.1 mg/dl, p = 0.04, LDL cholesterol 111.83±42.46 mg/dl dl vs 100.56±37.99 mg/dl, p = 0.04. TG and HDL-C did not differ between the groups. TG: 223.39±130.76 vs 189.69±122.18 p = 0.057. HDL-C: 41.92±13.54 mg/dl vs 43.30±12.87 mg/dl, p = 0.48. In the group of patients with hyperuricemia, there was a significantly high level of glucose compared with patients with normal levels of uric acid: 9.71±04.35 mmol/l vs 6.51±3.06 mmol/l, p = 0.0001. The creatinine level was also high in patients with hyperuricemia: 98.45±36.75 μmol/l vs 85.06±17.21 μmol/l, p = 0.003.

Conclusions:
Hyperuricemia should be considered as an additional cardiovascular risk in hypertensive patients. Hyperuricemia is associated with severe dyslipidemia and elevated levels of glycemia and creatinine in hypertensive patients.
LEVELS OF THE ADIPOKINE CHEMERIN HELP TO PREDICT PREECLAMPSIA AND ITS COMPLICATIONS
Authors: Tan Lunbo , Neuman Rugina I. , Schoenmakers Sam , Danser A.H. Jan , Verdonk Koen 
Published: June 2023

Objective:
The adipokine chemerin is increased in preeclampsia (PE). Here, we evaluated its potential as a biomarker to predict PE or fetal complications.

Design and method:
We measured chemerin in 523 women with suspected or confirmed PE, as a secondary analysis of a prospective cohort study that evaluated the use of the sFlt-1 (soluble Fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio. The concordance (c)-statistic was used to evaluate the predictive value of chemerin or the sFlt-1/PlGF ratio on top of the traditional clinical risk factors (TCF) model involving gestational age, parity, proteinuria, and mean arterial pressure (MAP).

Results:
At the time of biomarker measurement, women had a median gestational age of 35.6 weeks (range 31.7-38.0). Serum chemerin was elevated (P<0.001) in women with confirmed PE (n = 152) or gestational hypertension (n = 95) vs. women without hypertensive disease of pregnancy (n = 276; 252±129 and 236±113 vs. 198±83 ng/mL). Moreover, serum chemerin levels were higher (P<0.001) in pregnancies with fetal growth restriction or fetal death (n = 78) vs. those without fetal complications (n = 361; 289±172 vs. 210±95 ng/mL). To predict PE, the TCF model yielded a C-index of 0.90, while adding chemerin or the sFlt-1/PlGF ratio to the model raised this to 0.95, with no further increase occurring when adding both at the same time. To predict fetal complications, the C-index was 0.76 for the TCF model only. This increased to 0.78 and 0.80 when adding chemerin and the ratio, respectively, and to 0.82 when adding both.

Conclusions:
Chemerin levels are elevated in women with PE and gestational hypertension, and chemerin levels might be used to predict PE and fetal complications.
SAFETY, FEASIBILITY, AND ACCEPTABILITY OF TELEMEDICINE FOR HYPERTENSION IN PRIMARY CARE: A PROOF-OF-CONCEPT AND PILOT RANDOMIZED CONTROLLED TRIAL (SATE-HT)
Authors: Lee Eric Kam-Pui , Wang Shuqi , Leung Maria , Leung Shuk-Yun , Han Jinghao , Leung Will , Hui Elsie , Mihailidou Anastasia , Tsoi Kelvin Kam-Fai , Wong Martin Chi-Sang , Wong Samuel 
Published: June 2023

Objective:
Hypertension (HT) continues to be a leading cause of cardiovascular death and an enormous burden on the healthcare system. Although telemedicine may provide improved blood pressure (BP) monitoring and control, it remains unclear whether it could replace face-to-face consultations in patients with optimal BP control. We hypothesized that an automatic drug refill coupled with a telemedicine system tailored to patients with optimal BP would lead to non-inferior BP control

Design and method:
In this pilot, multicenter, randomized control trial (RCT), participants receiving anti-HT medications were randomly assigned (1:1) to either the telemedicine or usual care group. Patients in the telemedicine group measured and transmitted their home BP readings to the clinic. The medications were refilled without consultation when optimal control (BP <135/85 mmHg) was confirmed. The primary outcome of this trial was the feasibility of using the telemedicine app. Office and ambulatory BP readings were compared between the two groups at the study endpoint. Acceptability was assessed through interviews with the telemedicine study participants.

Results:
Overall, 49 participants were recruited in 6 months and retention rate was 98%. Participants from both groups had similar BP control (daytime systolic BP: 128.2 versus 126.9 mmHg [telemedicine vs. usual care], p = 0.41) and no adverse events. Participants in the telemedicine group had fewer general outpatient clinic attendances (0.8 vs. 2, p<0.001). Interviewees reported that the system was convenient, timesaving, cost saving, and educational.

Conclusions:
The system could be safely used. However, the results must be verified in an adequately powered RCT.
RELATIONSHIP OF T704C AGT GENE POLYMORPHISM WITH RESISTANT ARTERIAL HYPERTENSION IN UZBEK POPULATION
Authors: Abdullaeva Guzal , Masharipov Shukhrat , Khamidullaeva Gulnoz , Yusupova Khafiza , Zakirova Darya , Abdullaev Alisher , Radjapova Guliruh 
Published: June 2023

Objective:
to study the association of T704C polymorphism of AGT gene with resistant arterial hypertension (AH) in Uzbek population.

Design and method:
Study included 178 patients with AH I–III degree of both sexes. The mean age of patients was 57.15 ± 11.01 years, duration of AH was 9.55 ± 5.75 years. Genotyping of the T704C polymorphism of the AGT gene was performed using real-time PCR using gene-specific primers of allele-specific probes. Relative risk (RR) was calculated using genetic models. Calculations were performed using the online program “Calculator for calculating statistics in case-control studies”. The results of all studies were considered statistically significant at p<0.05.

Results:
Patients were divided into two groups: 1 - patients with resistant AH (cases, n = 61) and 2 - patients with controlled hypertension (controls, n = 117). TT genotype - determined in 16.4%, TC genotype - in 32.8%, CC genotype - 50.8%, 2 = 16.279, p = 0.000. The allelic distribution showed the predominance of C allele: C allele - 67.2%, T allele - 32.8%, ⇙2 = 27.557, p = 0.000. In group 2, C allele in 52.6%, T allele in 47.4%, respectively, ⇙2 = 1.034, p = 0.309. The ratio of TT:TC:CC- genotypes was as follows: 20.5%: 53.8%: 25.6%, ⇙2 = 33.923, p = 0.000. An analysis revealed an association of the C allele T704C of the AGT gene polymorphism with resistant AH. 61 patients with resistant AH of group 1, the C allele was more common than in patients with of group 2 (67.2%; ⇙2 = 7.05; P = 0.008; OR = 1.85, 95% CI 1.17-2.92) and 32.8% had T allele. Accumulation of CC genotype among patients of group 1 (50.8%; ⇙2 = 11.59; P = 0.003; OR = 3.00, 95% CI 1.56-5.75), while TC genotype was found in 32, 8% of cases and TT genotype in 16.4% of cases. Whereas in the 2nd group, the CC genotype was less common - in 25.6% of cases than the TCgenotype (53.8%) cases.

Conclusions:
The results obtained indicate a significantly greater accumulation of the C-allele of T704C polymorphism of the AGT gene among patients with resistant hypertension. The C allele and CC genotype T704C of AGT gene polymorphism are associated with resistant hypertension in the Uzbek population.
EFFECTS OF TRIATHLON TRAINING ON HEMODYNAMIC RESPONSES AND VASCULAR FUNCTION: THE ATHLAS STUDY
Authors: Piscitello Tessy Cuffaro , Azzi Julien , Dupont Anne Charlotte , Salvi Paolo , Labat Carlos , Mandry Damien , Poussel Mathias , Mejri Menel , Benetos Athanase , Joly Laure 
Published: June 2023

Objective:
Regular and moderate endurance exercise has beneficial effects on the cardiovascular system. Triathlon is a rigorous endurance multisport that requires a higher level of training. Chronic consequences on cardiovascular system of such a high cardiovascular demand have not yet been highlighted. In this study, we assessed the effect of triathlon training and racing on the cardiovascular system in experienced triathletes.

Design and method:
ATHLAS is a prospective controlled study comparing 34 male recreational long-distance triathletes aged 19 to 39 years (Tri) with 29 healthy insufficiently active of the same age (Ctrl). All volunteers completed three visits throughout an annual sports season: at baseline during the off-season (in winter), at peak of physical performance during races period (in spring/summer), and during active rest in post-season (in autumn). At each visit, peripheral blood pressure was measured, and applanation tonometry was performed to evaluate arterial stiffness by carotid-femoral pulse wave velocity (cfPWV) and myocardial perfusion using the subendocardial viability ratio (SEVR).

Results:
At baseline, Tri had higher systolic blood pressure (SBP) and pulse pressure (PP) than Ctrl (respectively, 131.1±8.9 vs 125.7±10.4 mmHg; and 56.5±12.8 vs 48.9±6.5 mmHg, p<0.05) but lower cfPWV (6.29 ±0.15 vs 6.95 ±0.16 m/sec, p<0.01). SEVR was increased in Tri indicating better myocardial perfusion (mean difference of 34.42%, p = 0.03). At peak of performance in Tri, SBP and PP were decreased (respectively, mean difference of 3.63 mmHg, and 3.36 mmHg, p<0.05), and returning to baseline levels in active rest. Tri cfPWV and SEVR were not influenced by training phases. In Ctrl group, SBP, PP and cfPWV exhibited seasonal variation with lower levels in spring/summer (p< 0.05).

Conclusions:
Triathlon training and racing have beneficial effects on arterial stiffness and myocardial perfusion regardless of time of season. In triathletes, increased SBP despite lower arterial stiffness (cfPWV) reflects adaptation of the athlete's heart with a high cardiac output. These results will require further study to determine whether high blood pressure could lead to negative cardiovascular impact in the long term.
ELEVATED PLATELET REACTIVITY IN PATIENTS WITH UNCONTROLLED HYPERTENSION: THE EFFECT OF CHA2DS2-VASC SCORE
Authors: Marketou Maria , Spatharaki Paraskevi , Nioti Eleni , Kalomoirakis Petros , Karagounis Thomas , Alifrangie Aggeliki , Zacharis Evaggelos , Fragiadak Kostas , Plevritaki Anthoula , Kampanieris Emmanouil , Kassotakis Spyridon , Pateromichelakis Themis , Maragkoudakis Spyros , Kalpadaki Christina , Kochiadakis George 
Published: June 2023

Objective:
Hypertension is associated with vascular and endothelial dysfunction that may result in a greater propensity for reactive platelets to cause thrombosis.
Purpose: The aim of this study was to evaluate multiple platelet activation pathways in hypertensive patients with different level of blood pressure control and cardiovascular risk factors.

Design and method:
Thirty nine uncontrolled (office SBP > 140 mmHg and ambulatory daytime SBP >135 mmHg, 27 males, aged 58 ± 9 years) and 32 well controlled (office SBP < 140 mmHg and ambulatory daytime SBP < 135 mmHg, 21 males, aged 58 ± 8 years) essential hypertensive patients were included in the study. Twenty four healthy individuals (12 males, aged 53 ± 10 years) were served as control group. Blood samples were obtained before and 48 hours after the procedure and platelet aggregation was tested in platelet rich plasma after activation with arachidonic acid (AA), adenosine diphosphate ADP), collagen (Col), epinephrine (Epi) and ristocetin (Risto), by using AggRAM Platelet Aggregation Analyzer.

Results:
Hypertensive patients showed elevated platelet reactivity in all platelet activation pathways compared to normotensive group (AA: 88.8 ± 6.8% versus 79.5 ± 7.3%, ADP: 86.8±9.1% versus 71.5±7.7%, Col: 86.5 ± 5.7% versus 73.9 ± 6.7%, Epi: 92.6±5.4% versus 80.5 ± 5.7%, Risto: 93.8 ± 6.8% versus 79.9 ± 6.3%, p <0.05 for all). Col, Epi and Risto platelet activation pathway showed a statistically significant increase in patients with uncontrolled hypertension compared to the group with well controlled hypertension (AA: 88.8 ± 6.1% versus 89.1 ± 4.1%, ADP: 89.8 ± 4.1% versus 87.5±4.7%, Col: 87.5±4.7% versus 81.9 ± 6.7%, Epi: 93.6 ± 4.4% versus 80.1 ± 5.7%, Risto: 94.8 ± 3.8% versus 80.9 ± 4.3%,). Notably, strong correlations were found between the Col platelet pathway activation and Risto platelet pathway activation and CHA2DS2-VASc score (r = 0.57, p <0.001 and r = 0.61, p <0.001, respectively) in hypertensive patients.

Conclusions:
Patients with uncontrolled hypertension showed elevated platelet reactivity. Patients with high CHA2DS2-VASc even without atrial fibrillation carry also a higher risk of thrombosis as indicated by the increased platelet aggregation under certain pathways of activation.
ISTO STUDY - INTENSIV-INTERMEDIATE STATIN THERAPY OBSERVATIONAL STUDY
Authors: Joaquim Meireles-Brandao , R. Meireles-Brandao Lucia , Rui Coelho , Francisco Rocha-Goncalves 
Published: June 2023

Objective:
lifestyle changes are frequently insufficient to reduce cardiovascular risk (CVR) in patients with dislipidemia. This study aims to characterize the long-term evolution of lipid profile and CVR of patients under primary prevention.

Design and method:
A retrospective study was performed of outpatients at a Portuguese cardiovascular risk clinic with > 2 CVRF, followed >2 years between 1995 and 2015 (Fig. 1). Intermediate-intensity statin therapy had initiated early, in accordance with the clinićs practice. After written informed consent was obtained, sociodemographic and clinical charecteristics were collected from medical charts, at baseline and last visit. Changes in lipid profile and CV risk scores (FRS, ASCVD, SCORE) were estimated. Associations between HDL-C or LDL-C changes and gender, age, observation times and treatments were assessed through bivariate analysis and multiple linear regression models.

Results:
Out of 516 participants with mean follow-up of 11.4 +/- 4.3 years, 56.6% were female and and received intermediate-intensity statins. Lipid profile showed statistically significant improvment, including median changes in LDL-C and HDL-C of - 77.0 mg/dl and +19 mg/dl, respectively. CVR also showed statistically significant improvements according to all scores. Statin therapy resulted in a mean HDL-C ncrease of 7.4 mg/dl (independently of gender and other treatments) and a mean LDL-C reduction of 51.8 mg/dl (irrespective of age and other treatments).

Conclusions:
Results from this long-term real-life study indicate that primary prevention, specifically early and continuous therapy with intermediate-intensity statins as an add-on to lifestyle interventions, was important in obtaining consistent and adequate metabolic correction in patients with additional risk factors.
SELF-MONITORING OF BLOOD PRESSURE AND FEEDBACK USING APP IN TREATMENT OF UNCONTROLLED HYPERTENSION: SMART APP STUDY
Authors: Choi Dong-Ju , Park Sungji , Yoon Minjae , Jo Sangho , Kim Eungju , Kim Soojoong 
Published: June 2023

Objective:
Self-monitoring of blood pressure (SMBP) is a reliable method used to assess blood pressure (BP) accurately. However, patients do not often know how to respond to the measured BP value. We developed a mobile application-based feedback for tailored recommendations and aimed to evaluate whether this feedback is superior to SMBP alone in terms of BP reduction and drug compliance improvement in patients with hypertension.

Design and method:
Self-Monitoring of and Feed-back using APP in TReatment of UnconTrolled Blood Pressure (SMART-BP) is a prospective, randomized, open-label, multicenter trial to evaluate the efficacy of SMBP-App compared with SMBP alone. In the SMBP alone group, the patients performed home BP measurement and receive the standard care, whereas in the SMBP-App group, the patients received additional recommendations from the application using feedback algorithm in response to the obtained BP value. The primary endpoints were mean home BP and adherence of antihypertensive medication. Follow-up visits were scheduled at 12 and 24 weeks after randomization.

Results:
Among total 173 patients (88 for SBMP-app and 85 for SMBP alone) with full-analysis set, 53% were men, and the mean age was 59.8 years. Baseline characteristics including BP were not significantly different between two groups. At 6 months, mean reduction in home systolic BP was significantly higher in SMBP-App group than SBMP alone group (-20.0±13.5 vs. -14.9±12.9, = 0.012). Also, SMBP-app group showed higher drug adherence value and proportion of adherence over 95% than in SMBP alone group (95.2% vs. 90.4%, P = 0.004; 72/88 vs. 46/85, P = 0.010). Reduction in home systolic BP at 3 months and office systolic BP at 3 months were also higher in SBMP-App, similar with primary end point.

Conclusions:
SMBP-App is superior to SMBP alone in terms of blood pressure reduction and improved drug adherence in patients with hypertension.
Intrauterine Insemination After Human Chorionic Gonadotropin Trigger or Luteinizing Hormone Surge
Authors: Potapragada Nivedita R. , Babayev Elnur , Strom Danielle , Beestrum Molly , Schauer Jacob M. , Jungheim Emily S. 
Published: June 2023

OBJECTIVE:
To assess the odds of pregnancy after intrauterine insemination (IUI) timed by ultrasound monitoring and human chorionic gonadotropin (hCG) administration compared with monitoring luteinizing hormone (LH) levels.

DATA SOURCES:
We searched PubMed (MEDLINE), EMBASE (Elsevier), Scopus (Elsevier), Web of Science (Clarivate Analytics), ClinicalTrials.gov (National Institutes of Health), and the Cochrane Library (Wiley) from the inception until October 1, 2022. No language limitations were applied.

METHODS OF STUDY SELECTION:
After deduplication, 3,607 unique citations were subjected to blinded independent review by three investigators. Thirteen studies (five retrospective cohort, four cross-sectional, two randomized controlled trials, and two randomized crossover studies) that enrolled women undergoing natural cycle, oral medication (clomid or letrozole), or both for IUI were included in the final random-effects model meta-analysis. Methodologic quality of included studies was assessed with the Downs and Black checklist.

TABULATION, INTEGRATION, AND RESULTS:
Data extraction was compiled by two authors, including publication information, hCG and LH monitoring guidelines, and pregnancy outcomes. No significant difference in odds of pregnancy between hCG administration and endogenous LH monitoring was observed (odds ratio [OR] 0.92, 95% CI 0.69–1.22, P=.53). Subgroup analysis of the five studies that included natural cycle IUI outcomes also showed no significant difference in odds of pregnancy between the two methods (OR 0.88, 95% CI 0.46–1.69, P=.61). Finally, a subgroup analysis of 10 studies that included women who underwent ovarian stimulation with oral medications (clomid or letrozole) did not demonstrate a difference in odds of pregnancy between ultrasonography with hCG trigger and LH-timed IUI (OR 0.88, 95% CI 0.66–1.16, P=.32). Statistically significant heterogeneity was noted between studies.

CONCLUSION:
This meta-analysis showed no difference between pregnancy outcomes between at-home LH monitoring and timed IUI.

SYSTEMATIC REVIEW REGISTRATION:
PROSPERO, CRD42021230520.